Brokerages expect Recro Pharma Inc (NASDAQ:REPH) to announce sales of $20.74 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Recro Pharma’s earnings, with the highest sales estimate coming in at $23.00 million and the lowest estimate coming in at $19.35 million. Recro Pharma reported sales of $19.54 million in the same quarter last year, which indicates a positive year over year growth rate of 6.1%. The firm is expected to report its next earnings report on Wednesday, May 8th.
On average, analysts expect that Recro Pharma will report full-year sales of $84.70 million for the current financial year, with estimates ranging from $80.80 million to $89.70 million. For the next financial year, analysts forecast that the firm will post sales of $131.44 million, with estimates ranging from $94.30 million to $171.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Tuesday, February 19th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.17. Recro Pharma had a negative net margin of 103.07% and a negative return on equity of 472.58%. The firm had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $16.01 million.
Several hedge funds have recently made changes to their positions in the company. Oppenheimer & Co. Inc. boosted its holdings in shares of Recro Pharma by 5.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 32,313 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 1,683 shares in the last quarter. Essex Investment Management Co. LLC boosted its holdings in shares of Recro Pharma by 1.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock valued at $1,830,000 after buying an additional 4,833 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Recro Pharma by 47.8% during the 4th quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 7,679 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Recro Pharma by 18.8% during the 4th quarter. Bank of New York Mellon Corp now owns 57,679 shares of the specialty pharmaceutical company’s stock valued at $410,000 after buying an additional 9,118 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Recro Pharma by 12.3% during the 4th quarter. Geode Capital Management LLC now owns 157,953 shares of the specialty pharmaceutical company’s stock valued at $1,121,000 after buying an additional 17,299 shares in the last quarter. Hedge funds and other institutional investors own 56.68% of the company’s stock.
Shares of Recro Pharma stock traded down $0.05 on Friday, hitting $9.01. The stock had a trading volume of 131,586 shares, compared to its average volume of 157,888. The company has a debt-to-equity ratio of 4.04, a quick ratio of 2.08 and a current ratio of 2.45. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The stock has a market capitalization of $201.23 million, a price-to-earnings ratio of -3.62 and a beta of -0.30.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.